Pharmacokinetics of a New Carbapenem, DA-1131, after Intravenous Administration to Rats with Uranyl Nitrate- Induced Acute Renal Failure
|
|
- Simon Snow
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p Vol. 42, No /98/$ Copyright 1998, American Society for Microbiology Pharmacokinetics of a New Carbapenem, DA-1131, after Intravenous Administration to Rats with Uranyl Nitrate- Induced Acute Renal Failure SO H. KIM, 1 HYUN J. SHIM, 2 WON B. KIM, 2 AND MYUNG G. LEE 1 * College of Pharmacy, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul , 1 and Research Laboratories, Dong-A Pharmaceutical Company, Ltd., 47 Sanggal-Ri, Kiheung-Up, Yongin-Gun, Kyunggi-Do , 2 Korea Received 21 May 1997/Returned for modification 31 December 1997/Accepted 23 February 1998 Because the physiological changes that occur in patients with acute renal failure could alter the pharmacokinetics of the drugs used to treat the disease, the pharmacokinetics of DA-1131, a new carbapenem antibiotic, were investigated after 1-min intravenous administration of the drug (50 mg/kg of body weight) to control rats and rats with uranyl nitrate-induced acute renal failure (U-ARF rats). The impaired kidney function was observed in U-ARF rats on the basis of physiological parameters observed by microscopy of the kidney and obtained by chemical analysis of the plasma. After a 1-min intravenous infusion of DA-1131, the concentrations in plasma and the total area under the plasma concentration-time curve from time zero to time infinity increased significantly in U-ARF rats compared with those in control rats (13,000 versus 4,400 g min/ml). This was due to the significantly slower total body clearance (CL) of DA-1131 (3.84 versus 11.4 ml/min/kg) from U-ARF rats than from control rats. The significantly slower CL of DA-1131 from U-ARF rats was due to both significantly slower renal clearance ( versus 4.95 ml/min/kg because of a significant decrease in the 8-h urinary excretion of unchanged DA-1131 [1.54 versus 43.8% of the intravenous dose] due to impaired kidney function, as proved by the significant decrease in creatinine clearance [ versus 4.29 ml/min/kg]) and significantly slower nonrenal clearance (3.80 versus 6.34 ml/min/kg because of a significant decrease in the metabolism of DA-1131 in the kidney) in U-ARF rats. The amounts of DA-1131 recovered from all tissues studied (except the kidneys) were significantly higher for U-ARF rats than for control rats; however, the ratios of the amount in tissue to the concentration in plasma (except those for the kidney, small intestine, and spleen) were not significantly different between the two groups of rats, indicating that the affinity of DA-1131 for rat tissues was not changed considerably in U-ARF rats. Downloaded from * Corresponding author. Mailing address: College of Pharmacy, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul , Korea. Phone: Fax: E- mail: leemg@plaza.snu.ac.kr. Drugs are eliminated from the body by metabolism (mainly in the liver) and/or excretion (mainly via the kidney by glomerular filtration and/or renal tubular secretion). It has been reported that the total body clearance (CL) renal clearance (CL R ) and/or nonrenal clearance (CL NR ) of drugs which were eliminated mainly by metabolism and by excretion were altered in rats with uranyl nitrate-induced acute renal failure (U-ARF rats). The drugs eliminated mainly by metabolism include propranolol (22), theophylline (12), amiodarone (8), diltiazem (19), azosemide (21), DA-125, a new anthracycline (17), and adriamycin (18). The drugs eliminated mainly by renal excretion include vancomycin (7) and methotrexate (20). Therefore, it could be expected that the pharmacokinetics and hence the pharmacodynamics of drugs could be altered in renal failure. It has been reported previously (17) that uranyl nitrate-induced acute renal failure causes both liver and kidney impairment in Sprague-Dawley rats on the basis of plasma chemistry data and tissue microscopy. DA-1131, (1R,5S,6S)-(2S,4S)-2-[(E)-3-methansulfonyl ami- no-1-propenyl]pyrrolidine-4-ylthiol-6-[(r)-1-hydroxyethyl]-1- methyl-1-carbapen-2-em-3-carboxylic acid (Fig. 1), a new carbapenem antibiotic, has a broad spectrum of activity against both the gram-positive and gram-negative organisms (10). DA was resistant to degradation by various types of -lactamases (4). DA-1131 was relatively stable against hydrolysis of ICR mouse, Sprague-Dawley rat, New Zealand White rabbit, beagle dog, and human renal dehydropeptidase I (DHP-I) compared with imipenem and meropenem (11). Judging from the V max /K m ratios, DA-1131 showed relatively greater resistance (compared with those of imipenem and meropenem) to mouse, rat, rabbit, dog, and human renal DHP-I; the ratios of DA-1131 for resistance to DHP-I were from 1.3 to 4.6 times greater than those of imipenem and meropenem (unpublished data). DA-1131 is now being evaluated in a preclinical study. DA-1131 was chosen as a model drug in the present study because approximately 50% of the intravenous dose was excreted via the kidneys in rats. Therefore, changes in both CL R and CL NR of the drug could be expected in U-ARF rats. The purpose of this study was to investigate the effect of uranyl nitrate-induced acute renal failure on the pharmacokinetics and tissue distribution of DA-1131 after intravenous administration to control and U-ARF rats. MATERIALS AND METHODS Chemicals. DA-1131 (as the HCl salt) was donated by the Research Laboratories of Dong-A Pharmaceutical Company (Yongin, Korea). Uranyl nitrate was purchased from BDH Chemicals Ltd. (Poole, England). The other chemicals were of reagent grade or high-performance liquid chromatography (HPLC) grade and were used without further purification. Animals. Male Sprague-Dawley rats (weight, 265 to 320 g) were purchased from Charles River Company (Atsugi, Japan). The rats were randomly divided into two groups, control and U-ARF rats. Induction of acute renal failure in rats by uranyl nitrate injection. Uranyl nitrate (the powder was dissolved in injectable normal saline solution to make a concentration of 0.5%), 1 ml/kg of body weight (5 mg/kg), was injected once via on October 14, 2018 by guest 1217
2 1218 KIM ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 1. Chemical structure of DA the tail veins of the rats to induce acute renal failure (17). The same volume of injectable normal saline solution was similarly injected into control rats. The rats were given food (Sam Yang Company, Seoul, Korea) and water ad libitum. Pretreatment of rats. In the early morning on the fifth day after the intravenous administration of uranyl nitrate or injectable normal saline solution, the carotid artery and the jugular vein of each rat were cannulated with polyethylene tubing (Clay Adams, Parsippany, N.J.) while the animals were under light ether anesthesia. Both cannulas were exteriorized to the dorsal side of the neck, where each cannula terminated with long silastic tubing (Dow Corning, Midland, Mich.). Both silastic tubes were covered with a wire to allow free movement of the rat. Each rat was housed individually in a rat metabolic cage (Daejong Scientific Company, Seoul, Korea) and was allowed to recover from anesthesia for 4 to 5 h before the study began. The rats were not restrained during the experimental period. Intravenous study. DA-1131 (the HCl salt powder was dissolved in injectable normal saline solution), 50 mg/kg, was administered intravenously over 1 min via the jugular veins of control rats (n 10) and U-ARF rats (n 13). The total injection volume was approximately 1 ml. Blood samples (0.12 ml) were collected via the carotid artery at 0 (to serve as a control), 1 (at the end of the infusion), 5, 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 min after intravenous administration. Approximately 0.25 ml of heparinized injectable normal saline solution (20 U/ml) was used to flush the cannula after the collection of each blood sample to prevent blood clotting. Blood samples were immediately centrifuged to reduce the blood storage effect (the change in the concentration of DA-1131 in plasma due to the time that elapsed between the times of collection and centrifugation of the blood sample) on the concentrations of DA-1131 in plasma due to degradation (14), and a 50- l aliquot of each plasma sample was stored at 70 C in a freezer (Revco ULT 1490 D-N-S; Western Mednics, Asheville, N.C.) until HPLC analysis of DA-1131 (16). At the end of 8 h after the intravenous administration of DA-1131, as much blood as possible was collected via the carotid artery and each rat was killed by cervical dislocation. The blood samples were immediately centrifuged and plasma was collected for the measurement of urea nitrogen, creatinine, total protein, and albumin levels. At the same time, the metabolic cage was rinsed with 20 ml of distilled water and the rinsed material was combined with the urine sample. After measuring the exact volume of the combined urine sample, two 0.1-ml aliquots of the combined urine sample were stored at 70 C in a freezer (Revco ULT 1490 D-N-S) until HPLC analysis of DA-1131 (16) and measurement of creatinine levels. At the end (8 h) of the experiment, the whole kidneys and livers of control and U-ARF rats were excised, rinsed or perfused with injectable normal saline solution, blotted dry with tissue paper, and weighed. Small portions of the liver and kidney were fixed in 10% neutral phosphate-buffered formalin and were processed for routine histological examination by hematoxylin-eosin staining. Study of distribution in tissue after intravenous administration. DA-1131 (the HCl salt powder was dissolved in injectable normal saline solution), 50 mg/kg, was also administered intravenously to additional control rats (n 7) and U-ARF rats (n 8) as described above. At 30 min after intravenous administration of the drug, as much blood as possible was collected from the carotid artery, and each rat was killed by cervical dislocation. Blood samples were immediately centrifuged and plasma was collected. Approximately 1 g each of brain, fat, heart, lung, stomach, small intestine, large intestine, liver, kidney, mesentery, muscle, and spleen was excised, rinsed or perfused with injectable normal saline solution to eliminate any blood remaining in the tissues (organs), blotted with tissue paper, and homogenized with 4 volumes of distilled water with a tissue homogenizer (Ultra-Turrax T25; Janke & Kunkel, IKA-Labortechnik, Staufeni, Germany). After centrifugation, two 50- l aliquots of the supernatant were stored in the freezer (Revco ULT 1490 D-N-S) at 70 C until HPLC analysis of DA-1131 (16). Plasma samples were also diluted with 4 volumes of distilled water. All the procedures were conducted at 4 C on an ice bath. HPLC assay. The DA-1131 in the biological samples was analyzed within 7 days by the previously reported HPLC method developed by our laboratory (16). The mobile phase, M KH 2 PO 4 -acetonitrile (9:1 [vol/vol]; ph 5.0), was run through a reversed-phased column at a flow rate of 0.8 ml/min, and the column effluent was monitored with a UV detector set at 300 nm. The retention time of DA-1131 was approximately 8.0 min. The detection limits of DA-1131 in human plasma, urine, and rat tissue homogenate were 0.1, 0.5, and 0.1 g/ml, respectively. The mean within-day coefficients of variation of DA-1131 in human plasma and urine were 2.85% (range, 1.76 to 5.04%) and 2.85% (range, 1.65 to 4.75%), respectively. The mean between-day coefficients of variation for the analysis of the same samples on 3 consecutive days were 2.30 and 4.29% in human plasma and urine, respectively. Measurement of total protein, albumin, urea nitrogen, and creatinine levels. Total protein, albumin, urea nitrogen, and creatinine levels in plasma and creatinine levels in urine were measured with an Hitachi 747 instrument (Hitachi, Tokyo, Japan). Pharmacokinetic analysis. The total area under the plasma concentrationtime curve (AUC) from time zero to time infinity (AUC 0 ) was calculated by the trapezoidal rule-extrapolation method (13); this method uses the logarithmic trapezoidal rule to calculate the area during the phase when the level in plasma is declining (1) and the linear trapezoidal rule for the phase when the level in plasma is rising. The area from the last datum point to infinity was estimated by dividing the last concentration measured in plasma by the terminal rate constant. A standard method (9) was used to calculate the following pharmacokinetic parameters; the time-averaged CL, the area under the first moment of the plasma concentration-time curve (AUMC 0 ), the mean residence time (MRT), the apparent volume of distribution at steady state (V SS ), the time-averaged CL R, and the time-averaged CL NR (13). The mean values of CL (3), V SS (2), and terminal half-life (t 1/2 ) (6) were calculated by the harmonic mean method. Creatinine clearance (CL CR ) was calculated by dividing the total amounts of creatinine excreted in urine over 8hbytheAUCfrom 0 to 8 h (AUC 0 8 ) for creatinine (the concentration of creatinine in plasma was measured 8 h after administration of the intravenous dose), assuming that the kidney function was stable during the 8-h experimental period. The kidney function seemed to be stable since the CL CR for the control rats (4.29 ml/min/kg; see Table 1) was very similar to the values reported in the literature (3 to 5 ml/min/kg) and the impaired kidney function in U-ARF rats continued from the third day to the fifth day after a single injection of uranyl nitrate into the rats (12, 17). Statistical analysis. Levels of statistical significance were assessed by the t test between two means for unpaired data. Significant differences were judged as a P value of less than All results are expressed as means standard deviations. RESULTS Induction of acute renal failure in rats. In the U-ARF rats in the present study, the impaired kidney function was obvious; the levels of urea nitrogen in plasma (205 versus 17.1 mg/dl) and kidney weight (1.02 versus 0.803% of body weight) increased significantly and the CL CR value ( versus 4.29 ml/min/kg) decreased significantly compared with those for control rats (Table 1). Impaired kidney function in U-ARF rats was also supported by kidney microscopy; extensive tubular TABLE 1. Values of physiological parameters for plasma and organ (liver and kidney) weight of control and U-ARF rats a Rat Body wt (g) Initial b Final c Urea nitrogen (mg/dl) Level in plasma Creatinine (mg/dl) Total protein (g/dl) Albumin (g/dl) CL CR Organ wt (% of body weight) Liver Kidney Control (n 10) U-ARF (n 13) d e e d e e e b Measured just before the administration of uranyl nitrate. c Measured on the fifth day after a single administration of uranyl nitrate. d P e P
3 VOL. 42, 1998 DA-1131 PHARMACOKINETICS IN ACUTE RENAL FAILURE RATS 1219 FIG. 2. Mean arterial plasma concentration-time profiles of DA-1131 after a 1-min intravenous infusion of the drug (50 mg/kg) to control rats (n 10; E) and U-ARF rats (n 13; F). Bars represent standard deviations., P necrosis was present. Similar results have also been reported elsewhere (5, 7, 8, 12, 22). However, no significant findings were found by liver microscopy for both groups of rats and kidney microscopy for control rats. In U-ARF rats, the levels of albumin (2.37 versus 3.15 g/dl) and total protein (4.71 versus 5.48 g/dl) in plasma decreased significantly compared with those in control rats (Table 1). Note that body weight gain decreased significantly for rats pretreated with uranyl nitrate (from 290 to 278 g) (Table 1). Pharmacokinetics of DA-1131 after intravenous administration. After intravenous administration of DA-1131 to control rats, the mean levels of DA-1131 in arterial plasma declined rapidly (Fig. 2), with a mean t 1/2 of 15.3 min (Table 2), and were detected only up to 2 h (Fig. 2) due to the sensitivity of our HPLC assay. However, in U-ARF rats they declined slowly (Fig. 2), with a mean t 1/2 of 61.5 min (Table 2), and were detected for up to 6 h (Fig. 2). The t 1/2 values were significantly different. The concentrations of DA-1131 in plasma were significantly higher in U-ARF rats than in control rats (Fig. 2), and this resulted in a significant increase in the AUC 0 (13,000 versus 4,400 g min/ml) and the AUMC 0 (948,000 versus 49,600 g min 2 /ml) for DA-1131 in U-ARF rats (Table 2). The CL (3.84 versus 11.4 ml/min/kg), CL R ( versus 4.95 ml/min/kg), and CL NR (3.80 versus 6.34 ml/min/kg) of DA-1131 were significantly slower in U-ARF rats (Table 2). The V SS of DA-1131 increased significantly in U-ARF rats (259 versus 124 ml/kg) (Table 2). Distribution of DA-1131 in tissue after intravenous administration. The mean amounts of DA-1131 recovered from all tissues studied except kidney were significantly higher in U- ARF rats than in control rats (Table 3). However, the ratios of the amount in tissue to the concentration in plasma (T/P ratios) for each tissue studied except the kidney, small intestine, d P b i.v., intravenous. c P Control (n 10) 4, ,600 11, U-ARF (n 13) 13,000 22,400 c 948, ,000 c c c c c d c c Rat AUC 0 ( g min/ml) AUMC 0 ( g min 2 /ml) Terminal t 1/2 (min) MRT (min) CL CL R CL NR VSS (ml/kg) XU 0 8 (% of i.v. b dose) TABLE 2. Pharmacokinetic parameters of DA-1131 after 1-min intravenous infusion of the drug at 50 mg/kg to control and U-ARF rats a
4 1220 KIM ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Amount of DA-1131 recovered from 30 min after a 1-min intravenous infusion of the drug (50 mg/kg) to control and U-ARF rats a Tissue Amt ( g/ml of plasma or g/g of tissue) recovered Control rats (n 7) U-ARF rats (n 8) Ratio b Plasma c 5.86 Brain ( ) d c ( ) 3.06 Fat ( ) c ( ) 9.94 Heart ( ) c ( ) 4.70 Kidney ( ) c ( c ) Large intestine ( ) c ( ) 5.13 Liver ( ) c ( ) 5.70 Lung ( ) c ( ) 4.89 Mesentery ( ) c ( ) 6.20 Muscle ( ) c ( ) 6.08 Small intestine ( ) e ( f ) 2.44 Spleen ( ) c ( c ) 10.5 Stomach ( ) c ( ) 6.77 b Ratio of amount for U-ARF rats to amount for control rats. c P d Numbers in parentheses are the mean standard deviation T/P ratios. e P f P and spleen were not significantly different between control and U-ARF rats. DISCUSSION The significant increase in the AUC 0 and AUMC 0 of DA-1131 in U-ARF rats was due to the significantly slower CL of DA-1131 (3.84 versus 11.4 ml/min/kg) in U-ARF rats (Table 2). The significantly slower CL in U-ARF rats was due to the significantly slower both CL R ( versus 4.95 ml/min/kg) and CL NR (3.80 versus 6.34 ml/min/kg) of DA-1131 in U-ARF rats (Table 2). The significantly slower CL R of DA-1131 in U-ARF rats could be due to the impaired kidney function; the CL CR value was significantly reduced ( versus 4.29 ml/ min/kg) in U-ARF rats (Table 2). The impaired kidney function in U-ARF rats resulted in a significant decrease in the amounts of unchanged DA-1131 excreted in urine over 8 h (X U0 8 ) compared with the amounts excreted unchanged from control rats (1.54 versus 43.8%) (Table 2). Similar results were also reported for DA-125 (17), adriamycin (18), methotrexate (20), and azosemide (21). Significant decreases in the values of CL, CL R, and/or CL NR after intravenous administration of vancomycin (7), amiodarone (8), diltiazem (19), azosemide (21), methotrexate (20), and DA-125 (17) to U-ARF rats have also been reported. The contribution of biliary excretion of unchanged DA-1131 to the CL NR of DA-1131 after intravenous administration of the drug to rats seemed to be minor, because less than 1.76% of the intravenous dose of DA-1131 was excreted as unchanged drug in bile over 8 h after the intravenous administration of DA-1131 at 200 mg/kg to four to six rats (15). Therefore, the CL NR of DA-1131 could represent the metabolic clearance of DA The significantly slower CL NR of DA-1131 in U-ARF rats could be due to the considerably slower metabolism of DA-1131 in rat kidney because rat kidney was one of the main organs into which DA-1131 disappeared (mainly due to metabolism) on the basis of an in vitro tissue homogenate study with Sprague-Dawley rats (14). The significant increase in the V SS of DA-1131 in U-ARF rats resulted in a significant increase in the t 1/2 (61.5 versus 15.3 min) and the MRT (71.0 versus 11.2 min) of DA-1131 in U-ARF rats (Table 2). This was not mainly due to the increase in the unbound fraction of DA-1131 in U-ARF rat plasma because the level of plasma protein binding of DA-1131 was considerably low in U-ARF rats (approximately 10% in Sprague-Dawley rat plasma) (15). DA-1131 was highly concentrated in the kidneys of the control rats (39.2 g per g of tissue), as reflected by the greaterthan-unity value of the T/P ratio (2.00) for the organ. This was expected because the kidney was the main organ excreting unchanged DA-1131 in rats (43.8% of the intravenous dose of DA-1131) (Table 2). The T/P ratios of DA-1131 for all rat tissues studied (except the kidneys) were less than unity for control rats, indicating that DA-1131 has a low affinity for rat tissues. This was supported by the considerably low value of V SS of DA-1131 (124 ml/min/kg) for control rats (Table 2). For U-ARF rats, the amounts of DA-1131 recovered from all tissues studied except the kidneys were significantly higher than those for control rats; however, the T/P ratios were not significantly different between the two groups of rats except for those for the kidneys, small intestine, and spleen (Table 3). These data indicate that the affinity of DA-1131 for rat tissues is not affected considerably by acute renal failure. ACKNOWLEDGMENTS This work was supported in part by the Korea Ministry of Science and Technology (HAN project), 1996 and We thank In Chull Lee (acting director, Department of Anatomical Pathology, Choong-Ang Hospital, Seoul, Korea) for histological examination of liver and kidney and Hae-ran Moon (president, Green Cross Reference Laboratory, Seoul, Korea) for the measurement of total protein, albumin, urea nitrogen, and creatinine levels. REFERENCES 1. Chiou, W. L Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6: Chiou, W. L New calculation method for mean apparent drug volume of distribution and application to rationale dosage regimens. J. Pharm. Sci. 68: Chiou, W. L New calculation method of mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci. 69: Choi, S. H., G. W. Kim, J. Y. Kim, G. J. Lim, D. Y. Chung, W. B. Kim, and J. Yang Interaction of DA-1131, a new carbapenem antibiotic, with bacterial -lactamases, abstr. p In Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology, Seoul National University, Seoul, Korea.
5 VOL. 42, 1998 DA-1131 PHARMACOKINETICS IN ACUTE RENAL FAILURE RATS Danhof, M., M. Hisaoka, and G. Levy Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 230: Eatman, F. B., W. A. Colburn, H. G. Boxenbaum, H. N. Posmanter, R. E. Weinfeld, R. Ronfeld, L. Weissman, J. D. Moore, M. Gibaldi, and S. A. Kaplan Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J. Pharmacokinet. Biopharm. 5: Engineer, M. S., D. W. Ho, and G. P. Bodey, Sr Comparison of vancomycin disposition in rats with normal and abnormal renal functions. Antimicrob. Agents Chemother. 20: Fruncillo, R. J., B. N. Swanson, R. Bernhard, C. Marchion, and R. K. Ferguson Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. J. Pharm. Sci. 75: Gibaldi, M., and D. Perrier Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y. 10. Kim, G. W., M. S. Chang, K. W. Lee, Y. S. Chong, and J. Yang Comparative in vitro antibacterial activity of DA-1131, a new carbapenem antibiotic (I), abstr. p In Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology, Seoul National University, Seoul, Korea. 11. Kim, J. Y., G. W. Kim, S. H. Choi, J. S. We, H. S. Park, and J. Yang Renal dehydropeptidase-i (DHP-I) stability and pharmacokinetics of DA- 1131, a new carbapenem antibiotic, abstr. p In Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology, Seoul National University, Seoul, Korea. 12. Kim, O. N Pharmacokinetics of theophylline in experimental acute renal failure rats (I). Yakhak Hoeji 35: Kim, S. H., Y. M. Choi, and M. G. Lee Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21: Kim, S. H., W. B. Kim, and M. G. Lee Stability, tissue metabolism, tissue distribution, and blood partition of DA-1131, a new carbapenem. Res. Commun. Mol. Pathol. Pharmacol. 90: Kim, S. H., J. W. Kwon, and M. G. Lee. Pharmacokinetics and tissue distribution of a new carbapenem, DA-1131, after intravenous administration to mice, rats, rabbits, and dogs. Biopharm. Drug Dispos., in press. 16. Kim, S. H., J. W. Kwon, J. Yang, and M. G. Lee Determination of a new carbapenem derivative, DA-1131, in plasma and urine by high-performance liquid chromatography. J. Chromatogr. Ser. B 688: Kim, Y. G., E. J. Yoon, W. H. Yoon, H. J. Shim, S. D. Lee, W. B. Kim, J. Yang, and M. G. Lee Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharm. Drug Dispos. 17: Lee, H. J., W. H. Paik, and M. G. Lee Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats. Res. Commun. Mol. Pathol. Pharmacol. 91: Lee, Y.-H., M.-H. Lee, and C.-K. Shim Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrateinduced acute renal failure. Pharm. Res. 9: Park, J. M., C.-H. Moon, and M. G. Lee Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Res. Commun. Mol. Pathol. Pharmacol. 93: Park, K. J., W. H. Yoon, S. H. Kim, W. G. Shin, and M. G. Lee. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharm. Drug Dispos., in press. 22. Terao, N., and D. D. Shen Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats. J. Pharmacokinet. Biopharm. 12: Downloaded from on October 14, 2018 by guest
Dose-Dependent Pharmacokinetics of Itraconazole after Intravenous or Oral Administration to Rats: Intestinal First-Pass Effect
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2004, p. 1756 1762 Vol. 48, No. 5 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.5.1756 1762.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationEffects of water deprivation on the pharmacokinetics of DA-8159, a new erectogenic, in rats INTRODUCTION
Effects of water deprivation on the pharmacokinetics of DA-8159, a new erectogenic, in rats Ji Young Kim 1, Yu Chul Kim 1, Myung Gull Lee 1, Jong Won Kwon 2, Moohi Yoo 2 1 College of Pharmacy and Research
More informationJ Pharm Pharmaceut Sci (www. cspscanada.org) 11 (1): , 2008
Effects of Diabetes Mellitus Induced by Alloxan on the Pharmacokinetics of Metformin in Rats: Restoration of Pharmacokinetic Parameters to the Control State by Insulin Treatment Young Hee Choi 1, Myung
More informationBACKGROUND AND PURPOSE
British Journal of Pharmacology DOI:10.1111/j.1476-5381.010.00913.x www.brjpharmacol.org RESEARCH PAPER Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationMultiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers
Journal of Antimicrobial Chemotherapy (1996) 37, 955-963 Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers Renli Teng, Theodore E. Liston and Stephen C. Harris Central Research
More informationBioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method
Asian Journal of Chemistry Vol. 19, No. 6 (2007), 4245-4250 Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method K.V. SUBRAHMANYAM*, P. MOHANRAJ, P. SANDHYARANI, V.S. SARAVANAN
More informationShort Communication. Abstract. Introduction
Short Communication JPP, 6: 76 7 The Authors JPP Royal Pharmaceutical Society Received November 8, Accepted February, DOI./j.-758..76.x ISSN -57 Relationship between lipophilicity and absorption from the
More informationFlecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationPHARMACOKINETIC STUDY OF DEXTROMETHORPHAN WITH URINARY EXCRETION
PHARMACOKINETIC STUDY OF DEXTROMETHORPHAN WITH URINARY EXCRETION Heesun CHUNG, Wonkyung YANG, Hwakyung CHOI, Wontack JIN, Sihnyoung SIHN, Youngchan YOO National Institute of Scientific Investigation, Seoul,
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationA Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep
A Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep Ali Eslami, DVM, PhD 1 Ali Rassouli, DVM, PhD 2 Behnam Meshki, DVM, PhD 1 Gholam Reza Shams, BSc
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationPharmacokinetics of propofol when given by intravenous
Br. J. clin. Pharmac. (199), 3, 144-148 Pharmacokinetics of propofol when given by intravenous infusion DENIS J. MORGAN', GWEN A. CAMPBELL2,* & DAVID P. CRANKSHAW2 'Victorian College of Pharmacy, 381 Royal
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More information6. Production or formation of plasma protein and clotting factors and heparin.
Liver function test Clinical pathology dr. Ali H. Liver function test The liver has many vital physiologic functions involving synthesis, excretion, and storage. When a disease process damages cells within
More informationPharmacokinetics of Ertapenem in Healthy Young Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2002, p. 3506 3511 Vol. 46, No. 11 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.11.3506 3511.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationTitle. Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): Issue Date Doc URL. Rights.
Title The Administration of Ciprofloxacin During Continuou Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): 243-245 Issue Date 2009-05 Doc URL http://hdl.handle.net/2115/43035
More informationF. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract
JJC Jordan Journal of Chemistry Vol. 4 No.4, 2009, pp. 357-365 Development and Validation of Analytical Method for Fluconazole and Fluconazole Related Compounds (A, B, and C) in Capsule Formulations by
More informationEffects of Morphine on the Disposition of Ampicillin in Mice
ANTMCROBAL AGENTS AND CHEMOTHERAPY, Oct. 1985, p. 489-493 Vol. 28, No. 4 0066-4804/85/100489-05$02.00/0 Copyright X) 1985, American Society for Microbiology Effects of Morphine on the Disposition of Ampicillin
More informationDetermination of Tetracyclines in Chicken by Solid-Phase Extraction and High-Performance Liquid Chromatography
Determination of Tetracyclines in Chicken by Solid-Phase Extraction and High-Performance Liquid Chromatography Application ote Food Safety Authors Chen-Hao Zhai and Yun Zou Agilent Technologies Co. Ltd.
More informationPharmacokinetics of Cefotaxime and Its Active Metabolite in
ANTIMICROBIAL AGNTS AND CHMOTHRAPY, Sept. 1991, p. 1879-1883 66-484/91/91879-5$2./ Copyright 1991, American Society for Microbiology Vol. 35, No. 9 Pharmacokinetics of Cefotaxime and Its Active Metabolite
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationDrug dosing in Extremes of Weight
Drug dosing in Extremes of Weight The Plump & Heavy versus The Skinny & Light Maria Minerva P. Calimag, MD, MSc, PhD, DPBA, FPSECP PROFESSOR Departments of Pharmacology, Anesthesiology and Clinical Epidemiology
More informationComparison of pharmacokinetics of gatifloxacin in rats, dogs and humans
Asian Journal of Drug Metabolism and Pharmacokinetics Paper ID 1608-2281-2005-05010071-06 Copyright by Hong Kong Medical Publisher Received November 20, 2004 ISSN 1608-2281 2005 5(1):71-76 Accepted February
More informationRP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol. 3, No.2, pp 605-609, April-June 2011 RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem
More informationSafety and Pharmacokinetics of CS-834, a New Oral Carbapenem Antibiotic, in Healthy Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1997, p. 2664 2669 Vol. 41, No. 12 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Safety and Pharmacokinetics of CS-834, a New Oral
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationScholars Research Library. Study of the effect of Ampicillin Trihydrate on protein binding of Oseltamivir Phosphate
Available online at www.scholarsresearchlibrary.com Der Pharmacia Lettre, 2011, 3(3): 320-324 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Study of the effect of Ampicillin
More informationHigh Performance Liquid Chromatographic Determination of Cyclooxygenase II Inhibitor Rofecoxib in Rat and Human Plasma
High Performance Liquid Chromatographic Determination of Cyclooxygenase II Inhibitor Rofecoxib in Rat and Human Plasma Saeed Sattari and Fakhreddin Jamali Faculty of Pharmacy and Pharmaceutical Sciences,
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationIII. TOXICOKINETICS. Studies relevant to the toxicokinetics of inorganic chloramines are severely
III. TOXICOKINETICS Introduction Studies relevant to the toxicokinetics of inorganic chloramines are severely limited. However, studies done with various chlorinated amino compounds (including organic
More informationClinical pharmacokinetics of meropenem after the first and tenth intramuscular administration
Journal of Antimicrobial Chemotherapy (1996) 37, 775-781 Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration A. Novelli', T. Mazzei', E. Meli*, S. Conti', S. Fallani'
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationFrancis Micheal et al /J. Pharm. Sci. & Res. Vol.3(7), 2011,
Bioavailability of Two Sublingual Formulations of Nitroglycerin.6 mg :A Randomized, Open-label, Single-dose, Two period, Crossover, Comparison in Healthy, Indian, Adult Volunteers. Francis Micheal*, Ganesan.
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More informationLund, 1948), the effect of which was to produce glomerular lesions without. relationship between increased protein loads and the tubular reabsorption
544 J. Phy8iol. (1961), 156, pp. 544-554 With 5 text-ftgure8 Printed in Great Britain TUBULAR REABSORPTION OF PROTEIN IN RATS WITH EXPERIMENTAL PROTEINURIA BY D. MENDEL* From the Department of Physiology,
More informationDate... Name... Group... Urine sample (Tube No 2)
Date... Name... Group... Instructions for the practical lesson on biochemistry Topic: Non-protein nitrogen compounds Task 1: Estimation of creatinine in serum and urine 1. Trichloroacetic acid 1.22 mol/l
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationC OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:
LESSON 2 Basic Pharmacokinetics C OBJECTIVES After completing Lesson 2, you should be able to: 1. Define the concept of apparent volume of distribution and use an appropriate mathematical equation to calculate
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationVancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1982, p. 575-58 66484/82/4575-6$2./ Vol. 21, No. 4 Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects ROBERT A. BLOUIN,1 LARRY A. BAUER,3* DELWYN
More informationNIH Public Access Author Manuscript Res Commun Chem Pathol Pharmacol. Author manuscript; available in PMC 2010 October 18.
NIH Public Access Author Manuscript Published in final edited form as: Res Commun Chem Pathol Pharmacol. 1986 July ; 53(1): 137 140. EFFECT OF BILE ON CYCLOSPORINE ABSORPTION IN DOGS Raman Venkataramanan
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationHPLC-UV Determination of Abacavir Sulphate in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 19, No. 5 (2007), 3412-3416 HPLC-UV Determination of Abacavir Sulphate in Pharmaceutical Dosage Forms A. SHANTA KUMARI*, K. PRAKASH, K.E.V. NAGOJI and M.E.B. RAO Department
More informationPharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor
Pharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor SI HYUNG YANG 1, JUNG HWA SUH 1, MYUNG GULL LEE 2 and SO HEE KIM 3 1 College
More informationSpectrophotometric Method for Estimation of Sitagliptin Phosphate in Bulk...
Spectrophotometric Method for Estimation of Sitagliptin Phosphate in Bulk... I J P F A International Science Press Spectrophotometric Method for Estimation of Sitagliptin Phosphate in Bulk and Tablet Dosage
More informationrins, had received prior successful antimicrobial therapy within the past 4 days, were receiving antimicrobial therapy
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1988, p. 73-735 Vol. 32, No. 5 66-484/88/573-6$2./ Copyright 1988, American Society for Microbiology St. Multiple-Dose Pharmacokinetics of Intravenously Administered
More informationThe pharmacokinetics and safety of intravenous voriconazole a novel wide-spectrum antifungal agent
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology1365-2125Blackwell Publishing 2356S129Original ArticlePharmacokinetics and safety of intravenous voriconazolel. Purkins et al.
More informationDRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION
DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION ROUTE OF DRUG ADMINISTRATION AND EXTRAHEPATIC DRUG METABOLISM The decline in plasma concentration after drug administration
More informationRenal Clearance and Urinary Excretion of Roxithromycin in Healthy Adult Female Subjects
Available online at www.scholarsresearchlibrary.com Central European Journal of Experimental Biology, 2017, 5 (1): 77-84 (http://www.scholarsresearchlibrary.com) ISSN:2278-7364 Renal Clearance and Urinary
More informationStudy on the Pharmacokinetics of Fasudil, a selective Rho kinase inhibitor
Asian Journal of Pharmacodynamics and Pharmacokinetics ISSN 1608-2281 Copyright by Hong Kong Medical Publisher Publisher Homepage: www.hktmc.com Study on the Pharmacokinetics of Fasudil, a selective Rho
More informationPharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator
BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 24: 121 129 (2003) Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.344 Pharmacokinetics and allometric scaling
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationRenal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion
59-291 Section 1, Lecture 5 Drug Excretion -most drugs are excreted in urine either as unchanged or drug metabolites Renal Function 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular
More informationOne-Compartment Open Model: Intravenous Bolus Administration:
One-Compartment Open Model: Intravenous Bolus Administration: Introduction The most common and most desirable route of drug administration is orally by mouth using tablets, capsules, or oral solutions.
More informationGastric, intestinal and colonic absorption of metoprolol in
Br. J. clin. Pharmac. (1985), 19, 85S-89S Gastric, intestinal and colonic absorption of metoprolol in the rat J. DOMENECH', M. ALBA', J. M. MORERA', R. OBACH' & J. M. PLA DELFINA2 'Department of Pharmaceutics,
More informationInternational Journal of Pharma and Bio Sciences
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE PHARMACEUTICAL ANALYSIS DEVELOPMENT AND VALIDATION OF LIQUID CHROMATOGRAPHIC METHOD FOR ESTIMATION OF ESCITALOPRAM OXALATE IN TABLET DOSAGE
More information(ethylene dinitrate) in the rat following
Brit. J. industr. Med., 1969, 26, 150-155 Metabolism of ethylene glycol dinitrate (ethylene dinitrate) in the rat following repeated administration D. G. CLARK AND M. H. LITCHFIELD Imperial Chemical Industries
More informationTamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali
10 Tamer Barakat Abdul Aziz ALShamali Abdul Aziz ALShamali Dr. Alia Elimination: Refampin is used to treat TB not malaria (Quinacrine is used for malaria) It s the opposite process of absorption. It's
More informationJ Pharm Sci Bioscientific Res (4): ISSN NO
Development and Validation of Analytical Methods for Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in their Combined Marketed Dosage form ABSTRACT: Nikhilkumar Patel, Gurjit Kaur,
More informationHyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.
International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2013 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/3/2013 Pharmacokinetics and Pharmacodynamics
More informationDetermination of free interstitial concentrations of piperacillin tazobactam combinations by microdialysis
Journal of Antimicrobial Chemotherapy (1998) 42, 769 778 Determination of free interstitial concentrations of piperacillin tazobactam combinations by microdialysis JAC Teresa Dalla Costa, Arno Nolting,
More informationPharmacokinetics of Sulfisoxazole in Renal Transplant Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1985, p. 535-539 66-484/85/1535-5$2./ Copyright 1985, American Society for Microbiology Vol. 28, No. 4 Pharmacokinetics of Sulfisoxaole in Renal Transplant Patients
More informationToxicity of intraperitoneal bisulfite
Toxicity of intraperitoneal bisulfite Studies were carried out in animals to investigate the toxicity of intraperitoneal bisulfite. The LDso (dose lethal to 50 per cent of the animals) for a single intraperitoneal
More informationApplied Biopharmaceutics & Pharmacokinetics Sixth Edition
Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Hill Leon Shargel, PHD, RPh Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Associate Professor, School of Pharmacy Virginia Commonwealth
More informationTEACHERS TOPICS Role of Protein Binding in Pharmacokinetics
TEACHERS TOPICS Role of Protein Binding in Pharmacokinetics Reza Mehvar, PhD School of Pharmacy, Texas Tech University Health Sciences Center Submitted January 3, 2005; accepted February 13, 2005; published
More informationDevelopment and Validation of RP-HPLC Method for the Estimation of Gemifloxacin Mesylate in Bulk and Pharmaceutical Dosage Forms
ISSN: 0973-4945; CODEN ECJHAO E-Journal of Chemistry http://www.e-journals.net 2010, 7(4), 1621-1627 Development and Validation of RP-HPLC Method for the Estimation of Gemifloxacin Mesylate in Bulk and
More informationStudy of the main chemical components of Ganoderma lucidum
Study of the main chemical components of Ganoderma lucidum Yasuo Komota et al Tokyo Medical and Dental University [Purpose] As part of the means for exerting quality control on Ganoderma lucidum 50% ethanol
More informationRenal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.
Renal Physiology April, 2011 J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine. Office : Room 105, Physiology Unit. References: Koeppen B.E. & Stanton B.A. (2010).
More informationPharmacokinetics of tetracycline hydrochloride after single intravenous injection in dogs
Short Paper Pharmacokinetics of tetracycline hydrochloride after single intravenous injection in dogs Rajaian, H. 1* ; Fazeli, M. 1 and Jalaee, J. 2 1 Department of Pharmacology, School of Veterinary Medicine,
More informationPrinciples of Toxicokinetics/Toxicodynanics
Biochemical and Molecular Toxicology ENVR 442; TOXC 442; BIOC 442 Principles of Toxicokinetics/Toxicodynanics Kim L.R. Brouwer, PharmD, PhD kbrouwer@unc.edu; 919-962-7030 Pharmacokinetics/ Toxicokinetics:
More informationMultiple Interactions of Cimetidine and Probenecid with Valaciclovir and Its Metabolite Acyclovir
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2002, p. 458 463 Vol. 46, No. 2 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.2.458 463.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/0128/96-FINAL July 1996 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CEFAPIRIN SUMMARY REPORT (1)
More informationStudy of the main chemical components of Ganoderma lucidum
Study of the main chemical components of Ganoderma lucidum Yasuo Komota et al Tokyo Medical and Dental University [Purpose] As part of the means for exerting quality control on Ganoderma lucidum 50% ethanol
More informationGastrointestinal side effects after intravenous erythromycin
Br. J. clin. Pharmac. (1986), 21, 295-299 Gastrointestinal side effects after intravenous erythromycin lactobionate K. M. DOWNEY & D. M. CHAPUT DE SAINTONGE Department of Pharmacology and Therapeutics,
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationThis revision also necessitates a change in the table numbering in the test for Organic Impurities.
Methylphenidate Hydrochloride Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 27 Jul 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationStability indicating RP-HPLC method development and validation of Etizolam and Propranolol hydrochloride in pharmaceutical dosage form
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationWorld Journal of Pharmaceutical Research
World Journal of Pharmaceutical ReseaRch Volume 3, Issue 3, 4527-4535. Research Article ISSN 2277 715 DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF RAMOSETRON Zarana
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationDrug elimination and Hepatic clearance Chapter 6
Drug elimination and Hepatic clearance Chapter 6 DRUG ELIMINATION Drugs are removed from the body by various elimination processes. Drug elimination refers to the irreversible removal of drug from the
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationAnalytical Method Development and Validation for the Estimation of Guaifenesin and Dextromethorphan by RP-HPLC
Human Journals Research Article September 2018 Vol.:13, Issue:2 All rights are reserved by Ramya Sree Borra et al. Analytical Method Development and Validation for the Estimation of Guaifenesin and Dextromethorphan
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More information